- More than 50 articles and interviews featuring Circio management have been published in the past year in over 30 widely read EU and US life science publications, with a combined readership of 14 million
- Circio was invited to publish a comprehensive review article in Nature Reviews Genetics summarizing the therapeutic potential of circular RNA
- Interviews with CEO Dr Erik Digman Wiklund featured in three prominent biotech industry podcasts
Oslo, Norway, 3 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that its strategy to raise awareness of the therapeutic potential of circular RNA across key life science stakeholders, continues to deliver broad coverage in top life science and biopharma media.
Over the past year, this effort has resulted in 57 published articles in 33 key life science industry publications, including three in-depth podcast interviews, covering recent partnerships, with Certest Biotec and 4basebio, and the launch of the latest circVec generation 3.0. These publications and podcasts have a combined biopharma following of 14 million stakeholders across the biopharma sector from biotech and pharma executives and investors to academic scientists, regulators, and policy think-tanks.
The most prominent recent articles and podcasts include:
The therapeutic potential of circular RNAs
Nature Reviews Genetics, 9 January 2025
Circio’s Vision For Long-Lasting Nucleic Acid Therapeutics
InVivo, the Citeline publication, 16 December 2024
Opinion: Circular RNA Will Soon Replace mRNA in Biopharma
BioSpace, 31 July 2024
Takeovers, Trump, and trends: how biopharma is likely to shift this year
BioXconomy, 1 January 2025
Forecasting Pharma’s Future
Drug Solutions podcast, PharmTech, 31 January 2025
Pivoting to RNA with Circio´s Dr. Erik Digman Wiklund
Business of Biotech podcast, 2 September 2024
“Since emerging from ‘stealth mode’, we have worked systematically to communicate our position as discoverers and leaders in the rapidly expanding circular RNA field,” said Erik Digman Wiklund, CEO of Circio. “This effort is continuing to bear fruit through a substantial number of articles and podcasts in industry media featuring Circio, as demonstrated in particular by the invitation to review the circular RNA therapeutics field in the prestigious scientific journal Nature Reviews Genetics. The broad coverage across multiple channels builds important visibility and validation for the circVec platform and its significant potential over conventional mRNA-based expression technology.”
The strategy to raise Circio´s profile and circular RNA awareness was initiated in 2024, following in vivo validation of Circio´s unique and powerful circVec expression system. Life science communications expert Neil Hunter is supporting Circio in these efforts through his decades of PR experience for raising awareness and generating media coverage for therapeutic developers across the life science sector.
In addition to the cited articles and podcasts, Circio has been covered in leading industry titles such as Endpoints, BioCentury, BioWorld, The Medicine Maker, Mergermarket, MedNous, Pharmaceutical Technology, News Medical, Drug Discovery World, Drug Discovery News, Drug Target Review, Technology Networks, BioPharma Reporter, News Medical, The Pharma Letter, Contract Pharma, Advancing RNA, BioPharm International, Pharmaphorum, BioPharma Reporter and Pharma Times. The combined readership of these titles exceeds 14 million life science stakeholders globally.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Neil Hunter – Hunter PR
Phone:+44 7821 255568
Email: neiljameshunter@gmail.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.